(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 April 2012 (12.04.2012)

PCT

(10) International Publication Number
WO 2012/046061 A2

(51) International Patent Classification:
C07K 14/435 (2006.01)

(21) International Application Number:
PCT/GB2011/051910

(22) International Filing Date:
5 October 2011 (05.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1016742.7 5 October 2010 (05.10.2010) GB

(71) Applicants *(for all designated States except US)*: **HEALTH PROTECTION AGENCY** [GB/GB]; Porton Down, Salisbury Wiltshire SP4 0JG (GB). **MICROPHARM LIMITED** [GB/GB]; Station Road Industrial Estate, Newcastle Emlyn Carmarthenshire SA38 9BX (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHONE, Clifford** [GB/GB]; Health Protection Agency, Porton Down, Salisbury Wiltshire SP4 0JG (GB). **ROBERTS, April** [GB/GB]; Health Protection Agency, Porton Down, Salisbury Wiltshire SP4 0JG (GB). **AHERN, Helen** [GB/GB]; Health Protection Agency, Porton Down, Salisbury Wiltshire SP4 0JG (GB). **MAYNARD-SMITH, Michael** [GB/GB]; Health Protection Agency, Porton Down, Salisbury Wiltshire SP4 0JG (GB). **LANDON, John** [GB/GB]; MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BX (GB).

(74) Agent: **MACLEAN, Martin**; Mathys & Squire LLP, 120 Holborn, London Greater London EC1N 2SQ (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,

[Continued on next page]

(54) Title: CLOSTRIDIUM DIFFICILE ANTIGENS

Figure 1



(57) Abstract: The present invention relates to recombinant *Clostridium difficile* antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a *C. difficile Toxin* A sequence or residues 1500-1851 of a *C. difficile* Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a *C. difficile Toxin* A sequence or within amino acid residues 1852-2366 of a *C. difficile Toxin* B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a *C. difficile Toxin* A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a *C. difficile Toxin* B. Also provided is the use of said antigens for the prevention/ treatment/ suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/ treatment/ suppression of CDI.

WO 2012/046061 A2

SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*